MedTrace Logo

Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization

NCT03305874 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2023-08-24

No results posted yet for this study

Summary

Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include reducing the amount of contrast agent used and using a hydration strategy during procedure. A computer-based risk tool has been developed which reports a risk score for the likelihood a person undergoing cardiac intervention gets CIN and a proposed corresponding hydration strategy to reduce the risk of CIN. The purpose of this study is to determine whether the rate of CIN decreases when the treating physician has access to this risk tool during the procedure.

Conditions

  • Contrast-induced Nephropathy

Interventions

OTHER

Exposure to CBCIN risk score

The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).

Sponsors & Collaborators

  • Philips Healthcare

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • John E. A. Blair, MD · University of Chicago

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-07
Primary Completion
2023-07-17
Completion
2023-07-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03305874 on ClinicalTrials.gov